MYD88 and ovarian carcinoma: Taken together with statistical data that chemotherapy is effective in inducing remission in patients with primary disease and that ovarian cancer recurrence is driven at least in part by the CD44+/MyD88+ EOC stem cells that survive chemotherapy, the demonstration that EOC stem cells succumb to glycolysis inhibitors suggests that the most optimal treatment schedule is to give these inhibitors after the first-line chemotherapy.